Brief: Kinnate Biopharma Inc. To Present Trial Design For Its Lead RAF Kinase Inhibitor Program At AACR-NCI-EORTC Virtual International Conference
30/09/2021 21:35
Sept 30 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. TO PRESENT TRIAL DESIGN FOR ITS
LEAD RAF
KINASE INHIBITOR PROGRAM AT AACR-NCI-EORTC VIRTUAL INTERNATIONAL
CONFERENCE
Source text for Eikon: ID:nGNX1fN8L0
Further company coverage: KNTE.O
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview